FDA OKs Teva and Ambit's IND for BRAF inhibitor; ArQule completes Phase III study recruitment;

 @FierceBiotech: Gene therapy = fountain of youth in mice. Article | Follow @FierceBiotech

 @RyanMFierce: Osiris got a "first" ever nod for a stem-cell drug in Canada, but the business implications appear small. More | Follow @RyanMFierce

 @JohnCFierce: The R&D revolution wants you: Bacon and eggs and drug research talk... what more can you ask for? More | Follow @JohnCFierce

> The FDA has given Teva Pharamceutical ($TEVA) and Ambit Biosciences approval for an Investigational New Drug app for their experimental BRAF inhibitor CEP-32496. Article

> ArQule ($ARQL) and partner Daiichi Sankyo has wrapped up recruitment of patients for their pivotal MARQUEE trial for the experimental drug tivantinib in combination with erlotinib for treating certain patients with a form of non-small cell lung cancer. Release

> Pharmos reports success in a Phase IIa study of its drug levotofisopam for treating hyperuricemia and gout. Release

Pharma News

 @FiercePharma: Momenta tops Boston Globe list of best-performing companies. Generic Lovenox made the difference. Story | Follow @FiercePharma

 @EricPFierce: What leads many employers' concerns for drug benefits? The huge jump in specialty drug expense, for starters. Piece | Follow @EricPFierce

> Generic floodgates open for Plavix in U.S. Article

> Warner Chilcott sues Watson to stop generic contraceptive. News

> Employers eye costs of specialty drugs. Story

Medical Devices News

 @FierceMedDev: As the debate over the device tax continues, a hospital group warns that devicemakers might try to game the system: Story | Follow @FierceMedDev

 @MarkHFierce: Folks, there's still time to submit your nominations for the FierceMedicalDevices Fierce 15 private device developers. Survey | Follow @MarkHFierce

 @DamianFierce: Rivals St. Jude and Medtronic are at it again, this time over study results for $STJ's EnligHTN: More | Follow @DamianFierce

> Medtronic: DOJ closes inquiry into Infuse sales practices. Article

> Boston Sci touts long-term safety of Promus stent, despite FDA warning. Story

> Devicemakers use crowdsourcing to get patient feedback. Item

And Finally… Looking for biomarkers of cancer prognosis, a group of scientists has decided to Google it. Report

Suggested Articles

After the loss of its longtime CEO at the start of the year, a morphing MorphoSys is now losing its CSO.

A new study shows how circular ecDNA outside of the chromosome in cancer cells drives oncogenes, making tumors more aggressive.

The U.K. is currently a leading European location for clinical trials but that position could be threatened by Brexit and other factors.